Indisulam is primarily investigated for its application in cancer therapy, particularly as an antitumor agent. It functions as a selective inhibitor of carbonic anhydrase IX, an enzyme often overexpressed in various solid tumors, making it a potential target for cancer treatment. By inhibiting this enzyme, Indisulam disrupts the pH regulation in cancer cells, hindering their growth and survival. Additionally, it has been studied for its role in inducing cell cycle arrest and apoptosis in tumor cells, offering a promising approach for targeted cancer therapies. Research is ongoing to explore its efficacy in treating cancers such as colorectal, lung, and breast cancer, either as a standalone treatment or in combination with other chemotherapeutic agents.